Skip to main content
. 2023 Apr 25;12(4):786–796. doi: 10.21037/tlcr-23-121

Table 2. Camrelizumab treatments.

Variables Total (n=403)
Treatment line, n (%)
   First line 126 (31.3)
   Second line 164 (40.7)
   Third or later line 113 (28.0)
Duration of treatment, weeks, median (range) 21.9 (12.1–35.3)
Treatment cycles, median [range] 6 [1–24]
Treatment patterns, n (%)
   Camrelizumab monotherapy 43 (10.7)
   Camrelizumab plus chemotherapy 261 (64.8)
   Camrelizumab plus others* 99 (24.6)

*, others including anti-angiogenesis therapy or plus chemotherapy, or targeted therapy.